Table 6.
Lipinski’s Rule of Five for ADME and Drug-Likeness Parameters for the Target Compounds and Anticancer Standards
| Target Compounds |
Lipinski’s Rule of Five | Drug-likeness | ||||||
|---|---|---|---|---|---|---|---|---|
| MW (g/mol) <500 | H-bond acceptors <10 |
H-bond donors <5 | MLog P<5 | Lipinski violations <2 |
GI absorption | BBB permeant | Bioavailability | |
| Caryophyllene oxide | 220.35 | 1 | 0 | 3.67 | 0 | High | Yes | 0.55 |
| α-pinene | 136.23 | 0 | 0 | 4.29 | 1 | Low | Yes | 0.55 |
| D-limonene | 136.23 | 0 | 0 | 3.27 | 0 | Low | Yes | 0.55 |
| Anticancer Standards | MW (g/mol) <500 |
H-bond acceptors <10 |
H-bond donors <5 | MLogP <5 |
Lipinski violations <2 |
GI absorption | BBB permeant | Bioavailability |
| Doxorubicin | 543.53 | 12 | 6 | -2.1 | 3 | Low | No | 0.17 |
| Temozolomide | 194.15 | 5 | 1 | -0.98 | 0 | High | No | 0.55 |